NIOX GroupCSSPF 77 EV-to-FCF is 15.93 as of Jun. 24, 2026. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 418 Medical Devices & Instruments companies, NIOX Group ranks better than 66.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NIOX Group's Enterprise Value is $298.24 Mil.
NIOX Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $18.72 Mil. Therefore, NIOX Group's EV-to-FCF for today is 15.93.
The historical rank and industry rank for NIOX Group's EV-to-FCF or its related term are showing as below:
CSSPF'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.94 Med: -0.56 Max: 153.66
Current: 16.08
During the past 13 years, the highest EV-to-FCF of NIOX Group was 153.66. The lowest was -6.94. And the median was -0.56.
CSSPF's EV-to-FCF is ranked better than 66.75% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.66
vs CSSPF: 16.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NIOX Group's share price for today is $0.79965.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NIOX Group EV-to-FCF Related Terms
NIOX Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for NIOX Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NIOX Group's EV-to-FCF falls into.
NIOX Group's current Enterprise Value is $298.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $18.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a EV-to-FCF of 15.93 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #139 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 33.3%.
Is NIOX Group's EV-to-FCF too high?
NIOX Group's current EV-to-FCF is 15.93. The Medical Devices & Instruments industry median EV-to-FCF is 22.66. NIOX Group's value of 15.93 is 29.7% below this industry median. Based on the distribution chart, NIOX Group ranks #139 out of 418 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #139 out of 418 companies for EV-to-FCF. This puts NIOX Group in the upper half of its industry. The industry median EV-to-FCF is 22.66. NIOX Group's value of 15.93 is 29.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.66, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current EV-to-FCF of 15.93 is 29.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current EV-to-FCF is 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current EV-to-FCF is 15.93 and 29.7% below the Medical Devices & Instruments industry median of 22.66. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NIOX Group (CSSPF), the current EV-to-FCF is 15.93 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
EV-to-FCF: 15.93
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 29.7% below the Medical Devices & Instruments median (#139 of 418)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
